Figure 2.
Risk of metachronous adenoma is reduced in people treated with DFMO and sulindac versus placebo. Percent recurrence in people treated with placebo are compared to those treated with both DFMO and sulindac. Data are summarized from [3]
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.